A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy and safety of intravenous Lucassin®
(terlipressin) versus placebo for the treatment of type 1 hepatorenal syndrome (HRS) in
subjects receiving standard of care albumin therapy.